کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6258181 | 1612966 | 2014 | 8 صفحه PDF | دانلود رایگان |
- Central 6-OHDA produced a notorious motor impairment in mice.
- Central administration of NPS attenuated 6-OHDA-induced motor impairments.
- This study candidates selective NPSR agonists as an innovative treatment for Parkinson disease.
Neuropeptide S (NPS) is a 20-aminoacid peptide that selectively activates a G-protein coupled receptor named NPSR. Preclinical studies have shown that NPSR activation promotes anxiolysis, hyperlocomotion, arousal and weakfullness. Previous findings suggest that dopamine neurotransmission plays a role in the actions of NPS. Based on the close relationship between dopamine and Parkinson disease (PD) and on the evidence that NPSR are expressed on brain dopaminergic nuclei, the present study investigated the effects of NPS in motor deficits induced by intracerebroventricular (icv) administration of the dopaminergic neurotoxin 6-OHDA in the mouse rotarod test. 6-OHDA injection evoked motor deficits and significantly reduced tyrosine hidroxylase (TH)-positive cells in the substantia nigra (SN) and ventral tegmental area. However, a positive correlation was found only between the motor performance of 6-OHDA-injected mice and the number of TH-positive cells in SN. The systemic administration of l-DOPAÂ +Â benserazide (25Â +Â 6.25Â mg/kg) counteracted 6-OHDA-induced motor deficits in mice. Similar to l-DOPA, the icv injection of NPS (0.1 and 1Â nmol) reversed motor deficits evoked by 6-OHDA. In conclusion, NPS attenuated 6-OHDA-induced motor impairments in mice assessed in the rota-rod test. We discussed the beneficial actions of NPS based on a putative facilitation of dopaminergic neurotransmission in the brain. Finally, these findings candidate NPSR agonists as a potential innovative treatment for PD.
Journal: Behavioural Brain Research - Volume 266, 1 June 2014, Pages 29-36